MacroGenics Enters Research Collaboration with Janssen to Develop Novel DART® Molecule
MacroGenics, Inc. (NASDAQ: MGNX) announced a collaboration with Janssen Biotech, Inc. to develop a preclinical bispecific molecule using its DART® platform. MacroGenics will receive a $20 million upfront payment and could earn up to $312 million in milestone payments and tiered royalties on product sales. This collaboration aims to leverage the combined expertise of both companies in creating innovative therapeutics outside oncology, targeting unmet patient needs. The agreement signifies a promising step in MacroGenics' strategic partnerships and growth potential.
- Collaboration with Janssen Biotech could lead to innovative therapeutics.
- $20 million upfront payment enhances liquidity.
- Potential to receive up to $312 million in milestone payments.
- Tiered royalties on worldwide product sales provide additional revenue stream.
- Details on the undisclosed targets remain unclear, adding uncertainty.
- Risks associated with the actual revenue generation from collaborations.
- Forward-looking statements caution against reliance on expected outcomes.
ROCKVILLE, MD, Dec. 18, 2020 (GLOBE NEWSWIRE) --
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced today a research collaboration and global license agreement to develop a preclinical bispecific molecule with Janssen Biotech, Inc. The research collaboration will incorporate MacroGenics' proprietary DART® platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology.
“We are excited to collaborate with Janssen, which we believe is a leader in the field of next generation antibody-based therapeutics, by bringing together our two companies' respective scientific talent and experience to leverage our DART platform to generate a compelling product candidate that addresses unmet patient needs,” said Scott Koenig, M.D., Ph.D., President and Chief Executive Officer of MacroGenics.
Under the terms of the agreement, Janssen will pay MacroGenics an upfront payment of
About MacroGenics, Inc.
MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics, the MacroGenics logo, and DART are trademarks or registered trademarks of MacroGenics, Inc.
Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development of the Company's therapeutic candidates, commercial prospects of or product revenues from MARGENZA, milestone or opt-in payments from the Company's collaborators, the Company's anticipated milestones and other statements containing the words "subject to", "believe", "anticipate", "plan", "expect", "intend", "estimate", "project", "may", "will", "should", "would", "could", "can", the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks that MARGENZA revenue, expenses and costs may not be as expected, risks relating to MARGENZA’s market acceptance, competition, reimbursement and regulatory actions, the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company's product candidates and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.
###
FAQ
What is the recent collaboration involving MacroGenics (MGNX)?
How much upfront payment did MacroGenics receive from Janssen?
What is the potential total gain for MacroGenics from this collaboration?
What does the agreement mean for MacroGenics' future?
What are the risks associated with the MacroGenics and Janssen collaboration?
